Outer membrane vesicles derived from E. coli as novel vehicles for transdermal and tumor targeting delivery.,Nanoscale

当前位置： X-MOL 学术 › Nanoscale › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Outer membrane vesicles derived from E. coli as novel vehicles for transdermal and tumor targeting delivery.
Nanoscale ( IF 5.8 ) Pub Date : 2020-08-18 , DOI: 10.1039/d0nr03698f
Ting-Wei Gu ₁ , Mao-Ze Wang , Jie Niu , Yang Chu , Ke-Ran Guo , Li-Hua Peng

Affiliation

Transdermal drug delivery is favored in clinical therapy because of its ability to overcome the shortcomings of the first pass elimination of the liver caused by traditional oral administration and the irreversibility of the injection. However, skin stratum corneum (SC) forms a big barrier that precludes most of the biomacromolecules. Herein, we propose the engineering of transformed Escherichia coli (E. coli) derived outer membrane vesicles, detoxified by lysozymes (named TEVs) as the carrier for transdermal drug delivery. TEVs were derived from transgenic E. coli and then modified by an integrin alpha(v)beta(3) (αvβ3) targeting peptide and co-loaded with indocyanine green (ICG) (P-TEVs-G). TEVs were shown to have excellence in penetrating through intact SC without any additional enhancement, followed by targeting of melanoma cells. TEVs are promising nanoplatforms for transdermal and tumor targeting drug delivery with high efficacy and biosafety, possessing great potential in the treatment of superficial tumors.

中文翻译：

大肠杆菌衍生的外膜囊泡，是经皮和靶向肿瘤的新型载体。

透皮药物递送在临床治疗中是受青睐的，因为其能够克服传统口服给药引起的肝脏首过消除的缺点以及注射剂的不可逆性。但是，皮肤角质层（SC）形成了很大的障碍，使大多数生物大分子无法实现。在本文中，我们提出了工程化的转化大肠杆菌（E. coli）衍生的外膜囊泡，经溶菌酶（命名为TEVs）解毒后作为透皮药物递送的载体。TEV源自转基因大肠杆菌然后通过整合素alpha（v）beta（3）（αvβ3）靶向肽进行修饰，并与吲哚菁绿（ICG）（P-TEVs-G）共同负载。研究表明，TEV具有出色的穿透完整SC的能力，并且没有任何其他增强作用，随后靶向黑色素瘤细胞。TEV是有前途的纳米平台，具有高效和生物安全性，可用于透皮和靶向肿瘤的药物输送，在浅表肿瘤的治疗中具有巨大潜力。

更新日期：2020-09-24

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11